These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18277954)

  • 1. Updated clinical practice guidelines on erythropoiesis-stimulating agents.
    Silver SM
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):945-6. PubMed ID: 18277954
    [No Abstract]   [Full Text] [Related]  

  • 2. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 3. Erythropoiesis-stimulating agents: creation and validation of a computerized prescriber order entry alert.
    Ensor CR; Kockler DR; Dugger RW; Hylton-Gravatt LA
    Ann Pharmacother; 2009 Jun; 43(6):1143-4. PubMed ID: 19458108
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoiesis-stimulating agents in cancer.
    Arcasoy MO
    J Clin Oncol; 2008 Jun; 26(18):3097-8; author reply 3098-100. PubMed ID: 18565902
    [No Abstract]   [Full Text] [Related]  

  • 6. Reconsideration of American Society of Clinical Oncology/American Society of Hematology Erythropoiesis-stimulating Agent Guidelines.
    Murray N; Klasa R
    J Clin Oncol; 2008 Jun; 26(18):3096-7. PubMed ID: 18565901
    [No Abstract]   [Full Text] [Related]  

  • 7. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 8. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 11. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
    Dicato M
    Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
    Singh AK
    Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
    [No Abstract]   [Full Text] [Related]  

  • 13. Reevaluating erythropoiesis-stimulating agents.
    Cotter DJ
    N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
    [No Abstract]   [Full Text] [Related]  

  • 14. Guidelines for guidelines.
    Amerling R; Winchester JF; Ronco C
    Blood Purif; 2007; 25(1):36-8. PubMed ID: 17170535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blind Pew sends a black spot: the current haemoglobin controversy.
    Stevens PE
    Blood Purif; 2008; 26(1):54-8. PubMed ID: 18182797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Black box warnings-implications in practice.
    Zarowitz BJ
    Geriatr Nurs; 2008; 29(6):402-9. PubMed ID: 19064138
    [No Abstract]   [Full Text] [Related]  

  • 17. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
    Smith JJ; Henderson JA
    J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect for oncology of the national coverage determination for erythropoiesis-stimulating agents.
    Jorgenson JA
    Manag Care Interface; 2008 Jul; 21(1):7-8. PubMed ID: 18727312
    [No Abstract]   [Full Text] [Related]  

  • 19. Distinguishing between clinical guidelines and covered services.
    Hood FJ
    South Med J; 2001 Jun; 94(6):590-3. PubMed ID: 11440326
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.